clinical trial · NCT06414460
Study of ISM3412 in Participants With Locally Advanced/Metastatic Solid Tumors
InSilico Medicine Hong Kong Limited·phase1·recruiting·n = 80
Locally Advanced/Metastatic Solid TumorsISM3412
brief summary
The study has consists of two parts, a dose escalation part (Part 1) and a dose selection optimization part (Part 2). The primary objectives of this study are to evaluate the safety and tolerability of ISM3412 in participants with locally advanced/metastatic solid tumors, and to determine the RP2D of ISM3412.
started
Apr 25, 2025
primary completion
Mar 31, 2028
completion
Mar 31, 2029
last updated
Dec 11, 2025
official title
A Phase 1, Open-Label, Multicenter, First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics/Pharmacodynamics, and Preliminary Efficacy of ISM3412 in Participants With Locally Advanced/Metastatic Solid Tumors
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol